BioStock: Cereno Scientific expands patent rights for CS1

With Cereno Scientific’s lead programme CS1 currently in phase II, the company is working towards future-proofing its commercial positioning. Throughout 2021, the biotech company has seen its patent portfolio for CS1 grow to cover most major global markets with the first two patent families. Last week, Cereno announced receiving its first patent in the third patent family for CS1.

Read the article at biostock.se:

https://www.biostock.se/en/2021/12/cereno-scientific-expands-patent-rights-for-cs1/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se